Equities Analysts Offer Predictions for RXRX Q2 Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Equities research analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for Recursion Pharmaceuticals in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.34) per share for the quarter, up from their previous forecast of ($0.40). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.92) EPS and FY2027 earnings at ($0.47) EPS.

A number of other equities analysts have also weighed in on RXRX. Needham & Company LLC dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Finally, Morgan Stanley cut their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and an average price target of $7.60.

Recursion Pharmaceuticals Stock Down 1.4 %

NASDAQ RXRX opened at $4.33 on Thursday. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.74 billion, a PE ratio of -2.83 and a beta of 0.99. The stock’s 50 day moving average is $5.53 and its 200 day moving average is $6.66.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. During the same period in the prior year, the company posted ($0.39) EPS. The company’s quarterly revenue was up 7.2% on a year-over-year basis.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of RXRX. Ensign Peak Advisors Inc grew its stake in shares of Recursion Pharmaceuticals by 0.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock valued at $2,774,000 after buying an additional 1,300 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after acquiring an additional 1,353 shares during the period. Summit Investment Advisors Inc. grew its position in Recursion Pharmaceuticals by 7.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after acquiring an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC grew its position in Recursion Pharmaceuticals by 9.8% in the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock valued at $113,000 after acquiring an additional 1,907 shares during the last quarter. Finally, Wedmont Private Capital increased its stake in Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after purchasing an additional 2,000 shares during the period. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.